Trials / Completed
CompletedNCT00424671
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Metabolism of a Single Dose of Licarbazepine
An Open-Label Study in Healthy Subjects and in Subjects With Stable Impaired Hepatic Function to Assess the Effect of Moderate Hepatic Impairment on Licarbazepine Pharmacokinetics and Metabolism After a Single Dose of 1000 mg Licarbazepine IR Tablets
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the influence of moderate hepatic impairment on the pharmacokinetics of licarbazepine after single oral administration in healthy subjects and in subjects with stable impaired hepatic function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Licarbazepine |
Timeline
- Start date
- 2006-11-01
- First posted
- 2007-01-19
- Last updated
- 2007-06-22
Locations
1 site across 1 country: Czechia
Source: ClinicalTrials.gov record NCT00424671. Inclusion in this directory is not an endorsement.